Protected: The evolving ovarian cancer treatment algorithm: What’s new for your patients in 2022?
This content is password-protected. To view it, please enter the password below. Password:
Browsing: Industry Spotlight
Tislelizumab plus chemo improved overall survival as first-line treatment for advanced oesophageal cancer in phase III study
Results from an interim analysis of the phase III RATIONALE 306 study, showed anti-PD-1 immune…
Protected: PBS listing for BRAFTOVI® (encorafenib) + cetuximab for metastatic colorectal (bowel) cancer patients with a BRAFV600 mutation(1)
This content is password-protected. To view it, please enter the password below. Password:
GenesisCare welcomes budget injection into diagnostic imaging, precision medicine, rural health workforce
GenesisCare, the largest provider of integrated cancer care in Australia, has today welcomed a raft…
FDA approves 1st, only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) approved nivolumab 360…
UK’s NICE recommends sotorasib for locally advanced or metastatic non-small cell lung cancer (NSCLC) within the cancer drugs fund
The National Institute for Health and Care Excellence (NICE) in the UK has published a…
NICE recommends nivolumab plus ipilimumab for untreated advanced kidney cancer in intermediate or poor-risk patients
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence…
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer,…
Protected: New first-in-class treatment for chronic graft-versus-host disease following stem-cell transplant
This content is password-protected. To view it, please enter the password below. Password:
Protected: New PBS listing expands access to Verzenio®
This content is password-protected. To view it, please enter the password below. Password: